Comparison of intermediate and high dose valaciclovir for the prophylaxis of CMV viraemia in allogeneic stem cell transplant recipients

ISRCTN ISRCTN78766104
DOI https://doi.org/10.1186/ISRCTN78766104
Secondary identifying numbers N0256114044
Submission date
12/09/2003
Registration date
12/09/2003
Last edited
30/11/2015
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Michael Potter
Scientific

Department of Haematology
The Royal Free & University Medical School
Pond Street
Hampstead
London
NW3 2QG
United Kingdom

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleComparison of intermediate and high dose valaciclovir for the prophylaxis of CMV viraemia in allogeneic stem cell transplant recipients
Study objectivesDoes high does valaciclovir four times daily have greater efficacy in reducing CMV viraemia than valaciclovir in allogeneic stem cell recipients?
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedInfections and Infestations: Cytomegalovirus (CMV) infection
InterventionRandomised controlled trial.
Intervention typeOther
Primary outcome measure1. Rate of CMV viraemia
2. Time to CMV viraemia
3. Incidence of CMV disease
4. Survival
Secondary outcome measuresNot provided at time of registration
Overall study start date03/07/2002
Completion date01/07/2004

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participants110
Key inclusion criteria110 patients, 55 in each treatment arm.
Key exclusion criteriaDoes not match inclusion criteria
Date of first enrolment03/07/2002
Date of final enrolment01/07/2004

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

The Royal Free & University Medical School
London
NW3 2QG
United Kingdom

Sponsor information

Department of Health (UK)
Government

Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom

Website http://www.doh.gov.uk

Funders

Funder type

Hospital/treatment centre

The Royal Free Hampstead NHS Trust (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

30/11/2015: no publications found on PubMed.